NO20012534L - Anvendelse av parvoviruskapsidpartikler ved inhiberingen av celleproliferering og migrering - Google Patents
Anvendelse av parvoviruskapsidpartikler ved inhiberingen av celleproliferering og migreringInfo
- Publication number
- NO20012534L NO20012534L NO20012534A NO20012534A NO20012534L NO 20012534 L NO20012534 L NO 20012534L NO 20012534 A NO20012534 A NO 20012534A NO 20012534 A NO20012534 A NO 20012534A NO 20012534 L NO20012534 L NO 20012534L
- Authority
- NO
- Norway
- Prior art keywords
- cells
- migration
- parvoviral capsid
- inhibition
- cell proliferation
- Prior art date
Links
- 210000000234 capsid Anatomy 0.000 title abstract 2
- 238000013508 migration Methods 0.000 title abstract 2
- 239000002245 particle Substances 0.000 title abstract 2
- 230000013152 negative regulation of cell migration Effects 0.000 title 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 230000010261 cell growth Effects 0.000 abstract 2
- 210000002889 endothelial cell Anatomy 0.000 abstract 2
- 108090000565 Capsid Proteins Proteins 0.000 abstract 1
- 102100023321 Ceruloplasmin Human genes 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 208000017733 acquired polycythemia vera Diseases 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000012010 growth Effects 0.000 abstract 1
- 230000003394 haemopoietic effect Effects 0.000 abstract 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 abstract 1
- 238000002513 implantation Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000005012 migration Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000037244 polycythemia vera Diseases 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 238000011476 stem cell transplantation Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9804022A SE520177C2 (sv) | 1998-11-24 | 1998-11-24 | Användning av tomma, icke-infektiösa, rekombinanta parvoviruskapsidpartiklar, eller P-antigenblockerande delar därav, för framställning av läkemedel för ihibering av hematopoietiska stamceller |
| PCT/IB1999/002112 WO2000030668A2 (fr) | 1998-11-24 | 1999-11-23 | Utilisation de particules de capsides de parvovirus dans l'inhibition de la proliferation et de la migration cellulaire |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20012534D0 NO20012534D0 (no) | 2001-05-23 |
| NO20012534L true NO20012534L (no) | 2001-06-29 |
Family
ID=20413393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20012534A NO20012534L (no) | 1998-11-24 | 2001-05-23 | Anvendelse av parvoviruskapsidpartikler ved inhiberingen av celleproliferering og migrering |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1131085A2 (fr) |
| JP (1) | JP2003516927A (fr) |
| KR (1) | KR20010080518A (fr) |
| CN (1) | CN1328469A (fr) |
| AU (1) | AU2566600A (fr) |
| CA (1) | CA2352043A1 (fr) |
| CZ (1) | CZ20011369A3 (fr) |
| HU (1) | HUP0104298A2 (fr) |
| IS (1) | IS5931A (fr) |
| MX (1) | MXPA01004949A (fr) |
| NO (1) | NO20012534L (fr) |
| PL (1) | PL348640A1 (fr) |
| SE (1) | SE520177C2 (fr) |
| WO (1) | WO2000030668A2 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1275658B1 (fr) * | 2001-07-10 | 2006-11-15 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Composé d'une variante de protéine VP1 de parvovirus et d'une protéine NS1 de parvovirus pour l'induction de cytolyse |
| EP1791858B1 (fr) * | 2004-09-24 | 2010-04-21 | Intercell AG | Proteine de capside vp1 modifiee du parvovirus b19 |
| CN101475942B (zh) * | 2008-11-28 | 2012-05-23 | 中国人民解放军第四军医大学 | 一种b19病毒vp1独特区基因 |
| US9598468B2 (en) | 2011-05-18 | 2017-03-21 | University Of Florida Research Foundation, Incorporated | Polypeptides and vectors for targeting HER2/neu expressing cells and uses thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL92298A (en) * | 1988-11-14 | 2001-04-30 | Us Secretary U S Dept Of Comme | Method for producing isolated empty b19 parvovirus capsids, introducing genes into cells utilizing the same, diagnostic assays for detecting parvovirus infection and an anti-parvovirus vaccine containing said capsids |
| NL8902301A (nl) * | 1989-09-14 | 1991-04-02 | Rijksuniversiteit | Humaan parvovirus b19 eiwitten, hun produktie en hun gebruik in diagnostische assays en vaccins. |
-
1998
- 1998-11-24 SE SE9804022A patent/SE520177C2/sv not_active IP Right Cessation
-
1999
- 1999-11-23 CA CA002352043A patent/CA2352043A1/fr not_active Abandoned
- 1999-11-23 HU HU0104298A patent/HUP0104298A2/hu unknown
- 1999-11-23 PL PL99348640A patent/PL348640A1/xx unknown
- 1999-11-23 JP JP2000583551A patent/JP2003516927A/ja active Pending
- 1999-11-23 CZ CZ20011369A patent/CZ20011369A3/cs unknown
- 1999-11-23 MX MXPA01004949A patent/MXPA01004949A/es unknown
- 1999-11-23 KR KR1020017006374A patent/KR20010080518A/ko not_active Withdrawn
- 1999-11-23 CN CN99813653A patent/CN1328469A/zh active Pending
- 1999-11-23 AU AU25666/00A patent/AU2566600A/en not_active Abandoned
- 1999-11-23 EP EP99968407A patent/EP1131085A2/fr not_active Withdrawn
- 1999-11-23 WO PCT/IB1999/002112 patent/WO2000030668A2/fr not_active Ceased
-
2001
- 2001-05-02 IS IS5931A patent/IS5931A/is unknown
- 2001-05-23 NO NO20012534A patent/NO20012534L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA01004949A (es) | 2003-03-10 |
| CN1328469A (zh) | 2001-12-26 |
| SE520177C2 (sv) | 2003-06-03 |
| WO2000030668A8 (fr) | 2000-09-14 |
| WO2000030668A3 (fr) | 2000-11-09 |
| NO20012534D0 (no) | 2001-05-23 |
| WO2000030668A9 (fr) | 2001-04-05 |
| CZ20011369A3 (cs) | 2001-10-17 |
| IS5931A (is) | 2001-05-02 |
| CA2352043A1 (fr) | 2000-06-02 |
| JP2003516927A (ja) | 2003-05-20 |
| WO2000030668A2 (fr) | 2000-06-02 |
| SE9804022D0 (sv) | 1998-11-24 |
| EP1131085A2 (fr) | 2001-09-12 |
| AU2566600A (en) | 2000-06-13 |
| HUP0104298A2 (hu) | 2002-03-28 |
| KR20010080518A (ko) | 2001-08-22 |
| PL348640A1 (en) | 2002-06-03 |
| SE9804022L (sv) | 2000-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kang et al. | Replicative senescence of normal human oral keratinocytes is associated with the loss of telomerase activity without shortening of telomeres | |
| Cummins et al. | HAUSP is required for p53 destabilization | |
| Roche et al. | Comparative proteomic analysis of human mesenchymal and embryonic stem cells: towards the definition of a mesenchymal stem cell proteomic signature | |
| US10900018B2 (en) | Means and methods for generation of breast stem cells | |
| Solana et al. | Molecular and cellular basis of immunosenescence | |
| CN102858964A (zh) | 多肽 | |
| Sanford et al. | A quest for the mechanism of “spontaneous” malignant transformation in culture with associated advances in culture technology | |
| Dogra et al. | Generating long‐lived CD8+ T‐cell memory: Insights from epigenetic programs | |
| Stellavato et al. | [Retracted] Novel Hybrid Gels Made of High and Low Molecular Weight Hyaluronic Acid Induce Proliferation and Reduce Inflammation in an Osteoarthritis In Vitro Model Based on Human Synoviocytes and Chondrocytes | |
| Fikry et al. | Bone marrow and adipose‐derived mesenchymal stem cells alleviate methotrexate‐induced pulmonary fibrosis in rat: comparison with dexamethasone | |
| Yang et al. | l‐Glutathione enhances antioxidant capacity of hyaluronic acid and modulates expression of pro‐inflammatory cytokines in human fibroblast‐like synoviocytes | |
| BR112022004562A2 (pt) | Método de seleção de doador universal para identificar doadores de células nk | |
| Ruef et al. | Granulocyte-macrophage colony-stimulating factor-dependent CD11c-positive cells differentiate into active osteoclasts | |
| WO2019210216A3 (fr) | Édition de gènes à base de talen et de crispr/cas pour la tyrosine kinase de bruton | |
| Zander et al. | Immortalized mouse cell lines that lack a functional Rev3 gene are hypersensitive to UV irradiation and cisplatin treatment | |
| NO20012534L (no) | Anvendelse av parvoviruskapsidpartikler ved inhiberingen av celleproliferering og migrering | |
| NO20060019L (no) | Fremgangsmater og preparater for interferonterapi | |
| Rakonczay Jr et al. | Chronic inflammation in the pancreas and salivary glands-lessons from similarities and differences in pathophysiology and treatment modalities | |
| Koch et al. | Modeling AEC—new approaches to study rare genetic disorders | |
| Zhang et al. | RSK-3 promotes cartilage regeneration via interacting with rpS6 in cartilage stem/progenitor cells | |
| Tang et al. | Gene expression signatures associated with suppression of TRAMP prostate carcinogenesis by a kavalactone‐rich Kava fraction | |
| Li et al. | Signaling on telomerase: a master switch in cell aging and immortalization | |
| Mahiddine et al. | CD99 isoforms regulate CD1a expression in human monocyte‐derived DCs through ATF‐2/CREB‐1 phosphorylation | |
| Parkinson | Telomerase as a novel and potentially selective target for cancer chemotherapy | |
| Yuan et al. | Chondrogenic differentiation and immunological properties of mesenchymal stem cells in collagen type I hydrogel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |